Menu
Search
|

Menu

Close
X

Celldex Therapeutics Inc CLDX.OQ (NASDAQ Stock Exchange Capital Market)

2.08 USD
+0.00 (+0.00%)
As of Jul 23
Previous Close 2.08
Open 2.23
Volume 34,000
3m Avg Volume 66,859
Today’s High 2.25
Today’s Low 2.05
52 Week High 11.55
52 Week Low 2.05
Shares Outstanding (mil) 13.77
Market Capitalization (mil) 30.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
10
FY17
13
FY16
7
EPS (USD)
FY19
-1.402
FY18
-15.748
FY17
-13.181
FY16
-19.020
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
4.41
8.16
Price to Book (MRQ)
vs sector
0.25
4.43
Price to Cash Flow (TTM)
vs sector
--
24.27
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.56
Return on Investment (TTM)
vs sector
-33.20
12.67
Return on Equity (TTM)
vs sector
-40.76
17.18

EXECUTIVE LEADERSHIP

Larry Ellberger
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Anthony Marucci
President, Chief Executive Officer, Director, Since 2008
Salary: $608,249.00
Bonus: $291,960.00
Sam Martin
Chief Financial Officer, Senior Vice President, Secretary, Since 2017
Salary: $327,615.00
Bonus: $115,000.00
Tibor Keler
Executive Vice President and Chief Scientific Officer, Since 2014
Salary: $434,453.00
Bonus: $140,000.00
Sarah Cavanaugh
Senior Vice President - Corporate Affairs and Administration, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

53 Frontage Rd Ste 220
HAMPTON   NJ   08827-4034

Phone: +1908.2007500

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

SPONSORED STORIES